151 related articles for article (PubMed ID: 29487009)
1. An immunohistochemical panel consisting of EZH2, C-KIT, and CD205 is useful for distinguishing thymic squamous cell carcinoma from type B3 thymoma.
Kim BS; Kim JK; Kang CH; Kim YT; Jung KC; Won JK
Pathol Res Pract; 2018 Mar; 214(3):343-349. PubMed ID: 29487009
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic utility of thymic epithelial markers CD205 (DEC205) and Foxn1 in thymic epithelial neoplasms.
Nonaka D; Henley JD; Chiriboga L; Yee H
Am J Surg Pathol; 2007 Jul; 31(7):1038-44. PubMed ID: 17592270
[TBL] [Abstract][Full Text] [Related]
3. The evaluation of immunohistochemical markers and thymic cortical microenvironmental cells in distinguishing thymic carcinoma from type b3 thymoma or lung squamous cell carcinoma.
Hayashi A; Fumon T; Miki Y; Sato H; Yoshino T; Takahashi K
J Clin Exp Hematop; 2013; 53(1):9-19. PubMed ID: 23801129
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma: diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms.
Kojika M; Ishii G; Yoshida J; Nishimura M; Hishida T; Ota SJ; Murata Y; Nagai K; Ochiai A
Mod Pathol; 2009 Oct; 22(10):1341-50. PubMed ID: 19648882
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical differentiation between type B3 thymomas and thymic squamous cell carcinomas.
Su XY; Wang WY; Li JN; Liao DY; Wu WL; Li GD
Int J Clin Exp Pathol; 2015; 8(5):5354-62. PubMed ID: 26191237
[TBL] [Abstract][Full Text] [Related]
6. CALML5 is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type B3 thymoma.
Kanamori K; Suina K; Shukuya T; Takahashi F; Hayashi T; Hara K; Saito T; Mitsuishi Y; Shimamura SS; Winardi W; Tajima K; Ko R; Mimori T; Asao T; Itoh M; Kawaji H; Suehara Y; Takamochi K; Suzuki K; Takahashi K
Thorac Cancer; 2023 Apr; 14(12):1089-1097. PubMed ID: 36924358
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical KIT (CD117) expression in thymic epithelial tumors.
Nakagawa K; Matsuno Y; Kunitoh H; Maeshima A; Asamura H; Tsuchiya R
Chest; 2005 Jul; 128(1):140-4. PubMed ID: 16002927
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic roles of MUC1 and GLUT1 in differentiating thymic carcinoma from type B3 thymoma.
Du MJ; Shen Q; Yin H; Rao Q; Zhou MX
Pathol Res Pract; 2016 Nov; 212(11):1048-1051. PubMed ID: 27688088
[TBL] [Abstract][Full Text] [Related]
9. Differential diagnostic value of CD5 and CD117 expression in thoracic tumors: a large scale study of 1465 non-small cell lung cancer cases.
Kriegsmann M; Muley T; Harms A; Tavernar L; Goldmann T; Dienemann H; Herpel E; Warth A
Diagn Pathol; 2015 Dec; 10():210. PubMed ID: 26643918
[TBL] [Abstract][Full Text] [Related]
10. Expression of proteasome subunit β5t in thymic epithelial tumors.
Yamada Y; Tomaru U; Ishizu A; Kiuchi T; Marukawa K; Matsuno Y; Kasahara M
Am J Surg Pathol; 2011 Sep; 35(9):1296-304. PubMed ID: 21836487
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and clinical significance of KIT(CD117) expression in thymic epithelial tumors in China.
Song N; Chen G; Zhang P; Liu M; He WX; Jiang GN
Asian Pac J Cancer Prev; 2012; 13(6):2745-8. PubMed ID: 22938452
[TBL] [Abstract][Full Text] [Related]
12. Vascular architecture as a diagnostic marker for differentiation of World Health Organization thymoma subtypes and thymic carcinoma.
Pfister F; Hussain H; Belharazem D; Busch S; Simon-Keller K; Becker D; Pfister E; Rieker R; Ströbel P; Marx A
Histopathology; 2017 Apr; 70(5):693-703. PubMed ID: 27791295
[TBL] [Abstract][Full Text] [Related]
13. Tumour eosinophilia combined with an immunohistochemistry panel is useful in the differentiation of type B3 thymoma from thymic carcinoma.
Khoury T; Chandrasekhar R; Wilding G; Tan D; Cheney RT
Int J Exp Pathol; 2011 Apr; 92(2):87-96. PubMed ID: 21044186
[TBL] [Abstract][Full Text] [Related]
14. Absence of gene mutations in KIT-positive thymic epithelial tumors.
Tsuchida M; Umezu H; Hashimoto T; Shinohara H; Koike T; Hosaka Y; Eimoto T; Hayashi JI
Lung Cancer; 2008 Dec; 62(3):321-5. PubMed ID: 18486988
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic utility of CD205 in breast cancer: Simultaneous detection of myoepithelial cells and dendritic cells in breast tissue by CD205.
Ohe R; Aung NY; Tamura Y; Kabasawa T; Utsunomiya A; Tamazawa N; Kitaoka T; Meng HX; Shibata K; Yamakawa M
Histol Histopathol; 2020 May; 35(5):481-488. PubMed ID: 31524947
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic significance of cell kinetic parameters in World Health Organization type A and B3 thymomas and thymic carcinomas.
Roden AC; Yi ES; Jenkins SM; Donovan JL; Cassivi SD; Garces YI; Marks RS; Aubry MC
Hum Pathol; 2015 Jan; 46(1):17-25. PubMed ID: 25455993
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.
Girard N; Shen R; Guo T; Zakowski MF; Heguy A; Riely GJ; Huang J; Lau C; Lash AE; Ladanyi M; Viale A; Antonescu CR; Travis WD; Rusch VW; Kris MG; Pao W
Clin Cancer Res; 2009 Nov; 15(22):6790-9. PubMed ID: 19861435
[TBL] [Abstract][Full Text] [Related]
18. EZH2 and POU2F3 Can Aid in the Distinction of Thymic Carcinoma from Thymoma.
Naso JR; Vrana JA; Koepplin JW; Molina JR; Roden AC
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190202
[TBL] [Abstract][Full Text] [Related]
19. Preferentially expressed antigen in melanoma as a novel diagnostic marker differentiating thymic squamous cell carcinoma from thymoma.
Taniguchi Y; Ishida M; Saito T; Ryota H; Utsumi T; Maru N; Matsui H; Hino H; Tsuta K; Murakawa T
Sci Rep; 2020 Jul; 10(1):12286. PubMed ID: 32704057
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy between B3 Thymoma and Thymic Carcinoma.
Hao Y; Si J; Jin J; Wei J; Xiang J; Xu C; Song Z
Curr Oncol; 2022 Dec; 29(12):9452-9460. PubMed ID: 36547157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
